We are excited to announce that Rochester Clinical Research (RCR) has been nominated again this year for the ‘Best Clinical Trial ​Company’ award at the Vaccine industry Excellence (ViE) Awards!  We are humbled by this and we know we could not do it without YOU, our fabulous partners and volunteers!  If you enjoy working with RCR please take a moment and lend your support by voting for us at this link:  LINK!

The awards – which will be held April 3-6, 2023 – celebrate groundbreaking achievements and research within the global vaccine industry. The winners are decided by a combination of public votes (YOU!) and recommendations from the awards’ scientific advisory board.

Following on from last year’s success

Last year, we were delighted for the nod from the congress as the #2 clinical trial site in the nation.  Adam Larrabee, President, RCR: “We are extremely pleased to be nominated for this prestigious award which confirms our achievements in continually setting standards of excellence and advocacy in the vaccine industry. We are working closely with so many of our honored peers, partners, and volunteers to safely and effectively unlock the world from this or any new threatening pandemic diseases and we will continue to invest to further develop new innovative solutions. In February 2022, RCR expanded to include a brand new 12,000 sf facility increasing our capacity to 31 exam rooms and 18 clinical study coordinators. This allowed us to broaden our unique offering to more vaccine, therapeutic and device trials to advance medicine and change lives in Rochester and around the world.”

After a particularly noteworthy year, we are confident that our excellent achievements will be recognized by all those who vote in the ViE Awards.  The RCR team is continuously contributing to a safer and healthier environment. If you wish to lend your support and vote for RCR, head to the ViE Awards website.
Please be aware that voting is open now and closes February 28.  Vote today!